PRESS RELEASES

Date Title View
Toggle Summary Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic
Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it
View HTML
Toggle Summary Chimerix, Inc. Announces Selection As A Top 5 Nominee For 2005 World Technology Award In Health And Medicine
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix, Inc. Supports Biodefense Legislation to Accelerate and Innovate Counterterrorism Products View HTML
Toggle Summary Chimerix Named a Red Herring Top 100 Private Company
- Award Recognizes Chimerix as a Top Company in North America that Drives the Technology Industry’s Future -
View HTML
Toggle Summary Chimerix Raises $11 Million
Chimerix Raises $11 Million SAN DIEGO, CA, November 4, 2004 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the
View HTML
Toggle Summary Chimerix Granted Patent for CMX001
Chimerix Granted Patent for CMX001 SAN DIEGO, CA, April 27, 2004 – Chimerix, Inc. and the University of California, San Diego (UCSD) announced today the issuance of U.S. Patent No. 6,716,825 entitled “Phosphonate Compounds” by the U.S. Patent and Trademark Office.
View HTML
Toggle Summary Chimerix Awarded NIH Grant
Chimerix Awarded NIH Grant SAN DIEGO, CA, March 11, 2004 - Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business
View HTML
Toggle Summary Chimerix Announces Licensing Deal
- Chimerix Obtains Rights to Cidofovir for Development of an Oral Drug to Treat Smallpox Infections -
View HTML
Toggle Summary CHIMERIX AWARDED $36.1M NIH Chimerix Awarded $36.1m NIH Grant To Develop Its Oral Drug For The Treatment Of Smallpox Infection
- Company Also Closes $3.1M Private Equity Financing
View HTML
Toggle Summary CHIMERIX, INC., ANNOUNCES APPOINTMENT OF EXPERT
- Company Currently Developing an Oral Drug for Sma
View HTML